Patients who develop intraprocedural stent thrombosis during PCI are at substantially higher risk of major adverse cardiovascular events for a month following the procedure, according to a study presented at the Transcatheter Cardiovascular Therapeutics meeting. Cangrelor will play an important role in treating intraprocedural stent thrombosis, according to SCAI past President Dr. J. Jeffrey Marshall, but it hasn't been approved by the FDA, leaving physicians to find other treatments for the complication in the meantime.

Related Summaries